Drugs / ABP 959
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03818607 | Jan 2019 → Jul 2022 | paroxysmal nocturnal hemoglobinuria | Amgen | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-08-23 | Amgen | AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 959, BIOSIMILAR CANDIDATE TO SOLIRIS® (ECULIZUMAB) amgen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABP 959 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03818607 ↗ |
| Route | Intravenous | “intravenous infusion” NCT03818607 ↗ |